Elmind Capital LP Purchases Shares of 130,000 Alumis Inc. $ALMS

Elmind Capital LP bought a new position in shares of Alumis Inc. (NASDAQ:ALMS) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 130,000 shares of the company’s stock, valued at approximately $3,658,200,000. Alumis accounts for about 0.9% of Elmind Capital LP’s portfolio, making the stock its 24th biggest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALMS. BlackRock Inc. purchased a new stake in shares of Alumis during the second quarter worth $231,259,000. MPM Bioimpact LLC purchased a new position in Alumis in the 4th quarter worth approximately $23,443,000. Janus Henderson Group PLC purchased a new position in Alumis in the 1st quarter worth approximately $46,790,000. Orbimed Advisors LLC acquired a new position in shares of Alumis during the 2nd quarter worth approximately $5,779,000. Finally, Woodline Partners LP grew its position in shares of Alumis by 809.7% in the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after purchasing an additional 1,558,660 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ALMS shares. Guggenheim boosted their price target on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Chardan Capital increased their price target on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. Wells Fargo & Company raised their price objective on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Citigroup reissued a “neutral” rating on shares of Alumis in a research report on Monday, August 17th. Finally, Wall Street Zen raised Alumis from a “strong sell” rating to a “hold” rating in a research note on Sunday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Alumis Stock Up 4.0%

ALMS opened at $23.96 on Wednesday. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -6.21 and a beta of -0.69. The business’s 50 day moving average is $26.57 and its two-hundred day moving average is $25.15. Alumis Inc. has a 52 week low of $3.76 and a 52 week high of $31.35.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). The business had revenue of $1.66 million for the quarter, compared to analyst estimates of $3.65 million. Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. Equities analysts expect that Alumis Inc. will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Roy C. Hardiman sold 2,692 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $70,988.04. Following the completion of the sale, the insider owned 207,746 shares in the company, valued at $5,478,262.02. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Christopher Bradley sold 2,572 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $67,823.64. Following the transaction, the insider owned 48,533 shares in the company, valued at $1,279,815.21. The trade was a 5.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is currently owned by insiders.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.